Clumps of alpha-synuclein, the protein responsible for nerve cell death in Parkinson’s disease, initially form under medium salt conditions. However, over time, these clumps, or aggregates, transform into droplets through a process called liquid-liquid phase separation (LLPS), effectively preventing further clumping, or aggregation, of alpha-synuclein, a study has shown.
A new collaboration dubbed the Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders, or simply AMP PDRD, will work to identify specific biomarkers that can differentiate Parkinson’s from other neurodegenerative disorders with similar symptoms. The goal, according to the Foundation…
U.S. Marine Corps and Navy personnel exposed to trichloroethylene (TCE) and other industrial chemicals in drinking water at Camp Lejeune in North Carolina face greater than twice the risk of experiencing accelerated Parkinson’s disease progression than individuals who were not exposed, a new study found. These findings add to…
Dopamine-producing nerve cells, or dopaminergic neurons, in the midbrain may play a role in the temporary storage of information in short-term memory, according to new data from a mouse study. This finding challenges the traditional understanding of these nerve cells, which were previously thought to function primarily in reward processing…
An intensive course in the Lee Silverman Voice Treatment, known as LSVT Loud, may be the best strategy to help people with Parkinson’s disease overcome speech and language problems, according to a trial from the University of Birmingham in the U.K. LSVT Loud, a program of vocal exercises developed…
Once-daily treatment with IRX4204, an oral small molecule being developed by Io Therapeutics, showed a potential to safely ease motor symptoms for most adults with early Parkinson’s disease taking part in a small, 30-day study. Building on this open-label Phase 1 clinical trial (NCT02438215), the company…
The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12…
Combining gait training with virtual reality and gamification elements — when game-like features are added to non-game activities — may help people with Parkinson’s disease see rehabilitation as a positive experience, a study suggests. That, in turn, could ultimately lead to better motor outcomes for patients, according to researchers.
People with a genetic predisposition to Parkinson’s disease are more likely to have early-onset symptoms, but lifestyle factors such as coffee consumption and tobacco and aspirin use may exert a more significant impact on that risk than common genetic risks, research findings suggest. While still exploratory, “our findings underline…
Two proteins, Aplp1 and Lag3, pair to allow toxic aggregates of alpha-synuclein — a hallmark of Parkinson’s disease — into nerve cells and help it spread across the brain, according to a study in mice. “Now that we know how Aplp1 and Lag3 interact, we have a new way…
Get regular updates to your inbox.